Literature DB >> 11500439

Association of interleukin-10 cytokine expression status with HLA non-DRB1*02 and Mycobacterium bovis BCG scar-negative status in south Indian pulmonary tuberculosis patients.

V Dheenadhayalan1, S Shanmugalakshmi, S Vani, P Muthuveeralakshmi, G Arivarignan, A D Nageswari, R M Pitchappan.   

Abstract

HLA DRB1*02 and its subtypes predispose individuals for a far-advanced sputum-positive pulmonary tuberculosis transcending ethnic boundaries. Mycobacterium bovis BCG does not afford the desired protection against adult pulmonary tuberculosis, and a spectrum of immune reactivity exists in controls and hospital contacts. All of these findings have been identified and demonstrated in areas of endemicity. Skewing of immunity from protective to pathogenic may involve a shift in the Th1-Th2 paradigm. To elaborate these ideas, we studied gamma interferon (IFN-gamma), interleukin-4 (IL-4), and IL-10 cytokine expression in 71 adult pulmonary tuberculosis patients and 74 controls from areas of endemicity in south India by 48-h microculture and reverse transcription-PCR. Most of the patients and controls expressed IFN-gamma de novo, and in the presence of purified protein derivative (PPD), all of them expressed significantly higher levels of IFN-gamma, suggesting a PPD-specific recall memory. HLA DRB1* allele-dependent IFN-gamma expression was identified only in controls, suggesting a skewing of the immune response in patients. In contrast to the case for IFN-gamma, only some patients and controls expressed IL-4 or IL-10 (Th2 profile); thus, the Th1 profile was identifiable only by a nonexpression of IL-4 or IL-10 in this area of endemicity. The Th2 profile was associated with HLA non-DRB1*02 and BCG scar-negative status in patients, attributing a significant risk (odds ratio = 2.074; 95% confidence interval = 0.612 to 7.07). It is possible that Mycobacterium tuberculosis (PPD)-specific IL-10 is expressed preemptively in unvaccinated (BCG scar-negative) individuals with a non-DR2 genetic background by chronic exposure in this area of endemicity and leads to pulmonary tuberculosis of adults.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500439      PMCID: PMC98679          DOI: 10.1128/IAI.69.9.5635-5642.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family.

Authors:  C M Greenwood; T M Fujiwara; L J Boothroyd; M A Miller; D Frappier; E A Fanning; E Schurr; K Morgan
Journal:  Am J Hum Genet       Date:  2000-07-05       Impact factor: 11.025

2.  The spectrum of immune response to M. tuberculosis in healthy individuals.

Authors:  L de S Fonseca; D R Biscaya; M H Saad; F M Martins
Journal:  Tuber Lung Dis       Date:  1992-08

3.  Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India.

Authors:  M Ravikumar; V Dheenadhayalan; K Rajaram; S S Lakshmi; P P Kumaran; C N Paramasivan; K Balakrishnan; R M Pitchappan
Journal:  Tuber Lung Dis       Date:  1999

4.  Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai.

Authors: 
Journal:  Indian J Med Res       Date:  1999-08       Impact factor: 2.375

5.  Protective effect of BCG against leprosy and its subtypes: a case-control study in southern Vietnam.

Authors:  N V Thuc; L Abel; V D Lap; J Oberti; P H Lagrange
Journal:  Int J Lepr Other Mycobact Dis       Date:  1994-12

6.  Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection.

Authors:  I M Orme; A D Roberts; J P Griffin; J S Abrams
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

7.  Tuberculosis prevention Trial, Madras.

Authors:  G V Baily
Journal:  Indian J Med Res       Date:  1980-07       Impact factor: 2.375

8.  Increased antimycobacterial immunity in interleukin-10-deficient mice.

Authors:  P J Murray; R A Young
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

9.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  3 in total

1.  Mycobacterium bovis BCG scar status and HLA class II alleles influence purified protein derivative-specific T-cell receptor V beta expression in pulmonary tuberculosis patients from southern India.

Authors:  S Shanmugalakshmi; V Dheenadhayalan; P Muthuveeralakshmi; G Arivarignan; R M Pitchappan
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 2.  Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.

Authors:  Helen McIlleron; Susan Abdel-Rahman; Joel Alex Dave; Marc Blockman; Andrew Owen
Journal:  J Infect Dis       Date:  2015-06-15       Impact factor: 5.226

3.  Protective immunity to Mycobacterium tuberculosis infection by chemokine and cytokine conditioned CFP-10 differentiated dendritic cells.

Authors:  Nasir Salam; Shashank Gupta; Sachin Sharma; Shweta Pahujani; Aprajita Sinha; Rajiv K Saxena; Krishnamurthy Natarajan
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.